Abstract: The present invention is concerned with a hog cholera virus vaccine comprising a polypeptide characteristic of hog cholera virus. Vector vaccines capable to express a nucleic acid sequence encoding such a polypeptide also form part of the present invention. Said polypeptide and nucleic acid sequence can also be used for the detection of hog cholera virus infection.

Abstract: This invention relates to a novel Eimeria protein with immunogenic properties as well as to DNA sequences encoding these proteins. This protein can be administered to poultry thereby protecting the birds against coccidiosis. In addition the DNA encoding this protein can be used for the preparation of a vector vaccine against coccidiosis.

Abstract: The invention relates to peptides or fragments thereof which are immunochemically reactive with Epstein-Barr Virus (EBV) antibodies. New antibodies directed to said peptides or fragments thereof are also part of the invention.The invention also relates to a method for the detection of EBV or antibodies directed against EBV in a test fluid and also to an immunochemical reagent comprising a peptide, a fragment or a polypeptide according to the invention and a test kit to be used when applying the said detection methods.Detection of EBV in a test fluid or tissue specimen using antibodies, monoclonal and polyclonal, directed to the said peptide, which have the characteristics of detecting both native and denatured EBV-EA protein is also part of said invention.

Abstract: The invention relates to a vaccine comprising an antigenic substance and a mixture of two adjuvants wherein one adjuvant is oil-based whereas the other adjuvant is water-based.

Abstract: A novel cell line chronically infected with HIV-2.sub.NIHZ virus secretes the precursor of the viral envelope proteins in extracellular medium. The cells grow well in serum-free medium which enables the concentration of the conditioned medium of the cells to be greatly increased (>100 fold). Such a concentration step is otherwise impossible to achieve if the cells are grown under conventional conditions using 10% fetal calf serum. A specific affinity procedure is provided to purify the gp160 protein from the concentrated conditioned medium of cultures of 100 liter batches using a mouse monoclonal antibody to the HIV-2 gp41 protein, which is a part of the gp160 protein. This purified HIV-2 gp160 reacts with high specificity and sensitivity with the anti viral antibodies of HIV-2 infected humans by several criteria such as i) ELISA, ii) western blot analysis, and iii) radioimmuno-precipitation of metabolically labeled gp160 from the same cell line.

Abstract: The invention relates to a sublingual or buccal pharmaceutical composition comprising trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz?2,3:6,7!oxepino-?4 ,5-c!pyrrole or a pharmaceutically acceptable salt thereof, and pharmaceutically acceptable auxiliaries suitable for use in sublingual or buccal compositions, and the use thereof for the manufacture of a sublingual or buccal pharmaceutical composition for the treatment of mental disorders, such as psychosis and schizophrenia.

Abstract: The invention relates to a composition comprising among others a fibrinopeptide A releasing compound. Furthermore the invention relates to the use of the composition as calibrator in plasma containing fibrinogen. A test kit comprising the said composition and a method to determine soluble fibrin also belong to the invention.

Abstract: The present invention provides a combination vaccine for use in the protection of poultry against ND comprising an expression system, such as a virus vector, expressing a NDV immunogenic protein, and a live NDV vaccine strain. It is demonstrated that such a combination vaccine affords good local and systemic protection.